IRIS
DE LUCA, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.863
EU - Europa 2.299
AS - Asia 1.591
SA - Sud America 96
Continente sconosciuto - Info sul continente non disponibili 9
AF - Africa 5
OC - Oceania 1
Totale 6.864
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.847
SG - Singapore 561
CN - Cina 516
UA - Ucraina 450
IE - Irlanda 435
GB - Regno Unito 340
TR - Turchia 337
SE - Svezia 278
IT - Italia 211
FR - Francia 180
DE - Germania 170
FI - Finlandia 111
IN - India 92
BR - Brasile 87
RU - Federazione Russa 75
VN - Vietnam 33
CA - Canada 14
CZ - Repubblica Ceca 14
HK - Hong Kong 14
IR - Iran 10
BE - Belgio 9
EU - Europa 9
CH - Svizzera 6
IL - Israele 5
BD - Bangladesh 4
GR - Grecia 4
PL - Polonia 4
AR - Argentina 3
AT - Austria 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
CL - Cile 2
EC - Ecuador 2
ID - Indonesia 2
IQ - Iraq 2
KZ - Kazakistan 2
LT - Lituania 2
MX - Messico 2
PK - Pakistan 2
RS - Serbia 2
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
DK - Danimarca 1
EG - Egitto 1
IM - Isola di Man 1
JO - Giordania 1
JP - Giappone 1
KR - Corea 1
LB - Libano 1
MA - Marocco 1
NL - Olanda 1
PH - Filippine 1
RO - Romania 1
TJ - Tagikistan 1
UY - Uruguay 1
VE - Venezuela 1
Totale 6.864
Salva come PNG Salva come JPEG
Città #
Jacksonville 511
Chandler 508
Dublin 431
Singapore 419
Southend 258
Izmir 192
Princeton 188
Nanjing 151
Wilmington 128
Ashburn 107
The Dalles 100
Beijing 94
Santa Clara 91
Cambridge 84
Dearborn 84
Nanchang 58
Ann Arbor 51
Woodbridge 51
New York 46
Altamura 45
Chieti 34
Dong Ket 33
Jiaxing 29
Los Angeles 29
Houston 26
Boardman 25
Shenyang 25
Helsinki 24
Norwalk 24
Tianjin 20
Grevenbroich 19
Kunming 19
Munich 18
Washington 17
Hebei 16
Hong Kong 13
Brno 12
Changsha 12
Hangzhou 12
Leawood 12
London 12
San Mateo 12
Ardabil 10
Nuremberg 10
Augusta 9
Cedar Knolls 9
Jinan 9
Torino 9
Brussels 8
Guangzhou 8
Lanzhou 8
Pescara 8
Teramo 8
Campobasso 7
Monmouth Junction 7
Toronto 7
Brooklyn 6
Falls Church 6
Frankfurt am Main 6
Fribourg 6
Montesilvano Marina 6
Ningbo 6
Changchun 5
Hanover 5
Orange 5
Rome 5
Taizhou 5
Zhengzhou 5
Ankara 4
San Francisco 4
San Vito Chietino 4
Stockholm 4
Turku 4
Warsaw 4
Belo Horizonte 3
Borgomanero 3
Boston 3
Curitiba 3
Düsseldorf 3
Florence 3
Milan 3
Mumbai 3
Oxford 3
Pelotas 3
Pianella 3
Rio de Janeiro 3
Shanghai 3
São Paulo 3
Tappahannock 3
Tashkent 3
Walnut 3
Almaty 2
Atlanta 2
Bangalore 2
Belgrade 2
Benevento 2
Boa Vista 2
Camerino 2
Campinas 2
Campo Grande 2
Totale 4.316
Salva come PNG Salva come JPEG
Nome #
Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid 135
IL 13 in multiple sclerosis 131
Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells 120
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 103
Effetti sinergici della terapia con interferone-beta sulla attivazione, adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante/remittente 101
La funzione soppressoria è ridotta nella polineuropatia demielinizzante cronica infiammatoria (CIDP) 99
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS) 97
Increasing age at disability milestones among MS patients in the MSBase Registry 97
Anti-glycolipid and anti-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy 96
Acetylcholine in multiple sclerosis: possible involvement in the modulation of the immune response and in oligodendrocyte recruitment. 96
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 96
Rantes Levels and mRNA Expression in Relapsing-Remitting Multiple Sclerosis (RR-MS): Effect of interferon Beta 1b (IFNBeta 1b) Treatment 95
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 93
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 92
Dysimmune demyelinating polyneuropathies: expression of adhesion molecules in sural nerves and changes in cellular immunity (suppressor cell function and cytokine mRNA expression) induced by treatment (progetto presentato a Telethon) 91
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. 90
Interferon β1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis 90
Chemokine production by mononuclear cells from relapsing-remitting multiple sclerosis (RR-MS) patients 89
Effect of TNF intraneural injection into the rat sciatic nerve 88
Rantes and MCP-1 Secretion by Mononuclear Cells of Patients with Nultiple Sclerosis 88
Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. 87
The Chieti experience with Interferon B1b (IFNB1b) during the first 2 years: side effects. 86
MCP-1 expression and secretion in adherent monocyte cultures from multiple sclerosis patients treated with interferon beta-1b 86
Interferon beta1b: the Chieti experience 85
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy 85
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 85
Interferon beta normalizes suppressor cell function in dysimmune neuropathies. 85
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 84
Effects of IL10 on recombinant interferon-beta1b stimulated suppressor cell function in MS and controls subjects 83
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 83
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 83
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 82
Effetti sinergici della terapia con interferone-beta sulla attivazione. Adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante /remittente. (C22) 82
Effect of rhTNF-alpha injection into rat sciatic nerve 82
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 82
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 81
Serum soluble adhesion molecules and proinflammatory cytokines are not increased in chronic inflammatory demyelinating polyneuropathy 80
Nail loss after teriflunomide treatment: a new potential adverse event 79
rlFN-beta-1B stimulated suppressor cell function in multiple sclerosis: effects of anti-IL-10 monoclonal antibody 77
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis 77
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 77
Shared T Cell Receptor Usage of Cerebrospinal Fluid Cells in Familial Multiple Sclerosis da: X° National A.I.N.I. Congress Association Italiana Neuroimmunologia - Florence, Italy, November 15/16,1999 76
JCV-Ab serostatus in MS patients treated with Natalizumab 76
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 76
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 76
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 75
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 75
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 74
Low dose oral methotrexate (MTX) in chronic progressive (CP) multiple sclerosis (MS) 74
Effect of rhTNF-a injection into rat sciatic nerve 72
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 72
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 72
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 72
Livelli sierici e liquorali di IL13 nella Sclerosi Multipla 70
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 69
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 69
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 69
Proteomic investigations on differential post-translational modification of transthyretin in multiple sclerosis. 69
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 68
Mononeuropathy following subcutaneous interferon-β injection 68
Contribution of metabolomics to multiple sclerosis diagnosis, prognosis and treatment 68
CD1A and CD1E gene polymorphisms are associated withsusceptibility to multiple sclerosis 67
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 67
IL-13 levels in serum and cerebro-spinal fluid of multiple sclerosis patients 66
Interferone beta1b: bilancio su un gruppo di 30 pazienti 65
Suppressor cell function is decreased in chronic inflammatory demyelinating polyneuropathy 65
Interferon β 1b: The Chieti experience 65
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. 64
Non-neuronal acetylcholine: a new modulator of immune responses in multiple sclerosis patients. 63
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 62
Effects of IFN-Beta on rantes and MCP-1 secretion by mononuclear cells frm patients with multiple sclerosis 62
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 60
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 60
Evaluation of suppressor cell function in chronicn inflammatory demyelinating polyneuropathy (CIDP) 58
A Multicentre italian study on efficacy and safety of Glatiramer Acetate in multiple sclerosis patients with allergic respiratory diseases 58
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. 56
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 55
Gestione degli effetti indesiderati della terapia con interferone beta nella sclerosi multipla 55
Epilepsy and multiple sclerosis: Clinical, radiological, electrophysiological and neuropsychological aspects 53
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 51
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 51
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients 50
Pregnancy and fetal outcomes after paternal exposure to disease modifying drugs for multiple sclerosis 50
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 48
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases 48
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 47
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 45
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis 45
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 43
Modulation of the immune response in multiple sclerosis patients: effect of non-neuronal acetylcholine 43
Pregnancy And Fetal Outcomes After Paternal Exposure To Disease Modifying Drugs For Multiple Sclerosis (P4.157) 38
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 38
Efficacy and safety of glatiramer acetate in multiple sclerosis patients with allergicrespiratory diseases. 37
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 31
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose 29
Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge 22
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 21
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 5
Totale 7.001
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.544
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.544
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020138 0 0 0 0 0 0 0 0 0 0 134 4
2020/2021616 86 0 91 1 37 123 1 2 80 68 58 69
2021/2022357 2 4 6 57 11 11 16 34 32 7 54 123
2022/20231.321 104 152 72 158 143 272 81 93 171 17 29 29
2023/2024653 46 30 38 16 37 225 145 30 0 31 5 50
2024/20251.367 117 317 334 26 34 65 42 59 123 94 156 0
Totale 7.001